KR20230024904A - Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 - Google Patents

Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 Download PDF

Info

Publication number
KR20230024904A
KR20230024904A KR1020227044068A KR20227044068A KR20230024904A KR 20230024904 A KR20230024904 A KR 20230024904A KR 1020227044068 A KR1020227044068 A KR 1020227044068A KR 20227044068 A KR20227044068 A KR 20227044068A KR 20230024904 A KR20230024904 A KR 20230024904A
Authority
KR
South Korea
Prior art keywords
seq
identical polypeptide
cdr2
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044068A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 디. 호
야오싱 황
리홍 리우
마노즈 에스. 나이르
펑페이 왕
지엔 위
양 루오
Original Assignee
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 filed Critical 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕
Publication of KR20230024904A publication Critical patent/KR20230024904A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C07K16/1045—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227044068A 2020-05-20 2021-05-20 Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 Pending KR20230024904A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US63/027,935 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US63/032,518 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US63/039,977 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US63/060,116 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US63/063,106 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US63/117,908 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US63/123,767 2020-12-10
US202163165729P 2021-03-24 2021-03-24
US63/165,729 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
KR20230024904A true KR20230024904A (ko) 2023-02-21

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044068A Pending KR20230024904A (ko) 2020-05-20 2021-05-20 Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도

Country Status (13)

Country Link
US (3) US20240002476A1 (enExample)
EP (1) EP4153625A4 (enExample)
JP (1) JP2023526469A (enExample)
KR (1) KR20230024904A (enExample)
AU (1) AU2021277373A1 (enExample)
BR (1) BR112022023467A2 (enExample)
CA (1) CA3184184A1 (enExample)
CL (1) CL2022003215A1 (enExample)
CO (1) CO2022018192A2 (enExample)
IL (1) IL298263A (enExample)
MX (1) MX2022014420A (enExample)
PH (1) PH12022500025A1 (enExample)
WO (4) WO2021236997A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CN101627055A (zh) * 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009128963A2 (en) * 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
EP3077051B1 (en) * 2013-12-02 2023-04-12 The Trustees of Columbia University in the City of New York Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
US10301377B2 (en) * 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MY201995A (en) * 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Also Published As

Publication number Publication date
WO2021236995A2 (en) 2021-11-25
JP2023526469A (ja) 2023-06-21
WO2021236997A3 (en) 2022-09-29
WO2021236995A3 (en) 2022-09-15
CL2022003215A1 (es) 2023-07-07
CO2022018192A2 (es) 2023-03-17
US20230203138A1 (en) 2023-06-29
WO2021236998A3 (en) 2021-12-16
WO2021236996A2 (en) 2021-11-25
MX2022014420A (es) 2023-03-21
PH12022500025A1 (en) 2024-03-25
WO2021236998A2 (en) 2021-11-25
AU2021277373A1 (en) 2023-01-05
CA3184184A1 (en) 2021-11-25
US20240002476A1 (en) 2024-01-04
WO2021236997A2 (en) 2021-11-25
US20230203134A1 (en) 2023-06-29
BR112022023467A2 (pt) 2023-03-28
WO2021236998A9 (en) 2022-03-31
IL298263A (en) 2023-01-01
EP4153625A4 (en) 2024-09-25
WO2021236996A3 (en) 2022-11-17
EP4153625A2 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP7684379B2 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
CN113874394B (zh) 抗体
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
WO2021236998A2 (en) Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
EP4206224A1 (en) Human antibody or antigen-binding fragment thereof against coronavirus spike protein
EP4585687A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
WO2020233715A1 (zh) 抗乙肝病毒抗体及其用途
US12523656B2 (en) Antibodies against SARS-CoV-2 spike protein
CN115028714A (zh) 一种检测冠状病毒的抗体及其应用
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
EP4108256A1 (en) Anti-ospa antibodies and methods of use
CN114751988A (zh) 中和冠状病毒的多特异性抗体
CN115087667A (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
CN116829177A (zh) 抗SARS-CoV-2的有效中和抗体及其生成和用途
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
WO2023077429A1 (en) TRIMERIC ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000